艾伏尼布 T3617

Product Introduction
Bioactivity


英文名: Ivosidenib

描述: Ivosidenib (AG-120) 是一种口服具有活力的异柠檬酸脱氢酶 1 的突变体酶 (mIDH1 enzyme) 抑制剂，能够使 d-2- hydroxyglutatrate (2-HG) 在体内降低。它具有良好的的安全性和临床活性，具有研究 AML 的潜力。

细胞实验: TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120. (Only for Reference)

体外活性: TF-1 cells or primary human AML patient samples expressing mutant IDH1 are treated with AG-120.Treatment with AG-120 decreases intracellular 2-HG levels, inhibites growth factor independent proliferation and restores erythropoietin (EPO)-induced differentiation in TF-1 IDH1-R132H cells. Similarly, pharmacological inhibition of mutant IDH1 enzyme with AG-120 in primary human blast cells cultured ex vivo provides an effective way to lower intracellular 2-HG levels and induces myeloid differentiation[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 100 mg/mL (171.54 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 50 mg/mL (85.77 mM)


关键字: Ivosidenib | inhibit | AG 120 | Inhibitor | AG120 | Isocitrate Dehydrogenase (IDH)

相关产品: Ammonium Glycyrrhizinate | Daidzin | Tiazofurin | Sodium dichloroacetate | 2-Pyridinecarbohydrazide | Physcion | ALDH1A3-IN-3 | Bipenquinate | Carbenoxolone | alpha-Mangostin

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Anti-Metabolism Disease Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | Hematonosis Compound Library | Lipid Metabolism Compound Library | EMA Approved Drug Library

艾伏尼布 T3617信息由TargetMol中国为您提供，如您想了解更多关于艾伏尼布 T3617报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途